Linden Thomas Advisory Services, LLC Halozyme Therapeutics, Inc. Transaction History
Linden Thomas Advisory Services, LLC
- $772 Billion
- Q1 2025
A detailed history of Linden Thomas Advisory Services, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Linden Thomas Advisory Services, LLC holds 35,881 shares of HALO stock, worth $2.01 Million. This represents 0.3% of its overall portfolio holdings.
Number of Shares
35,881
Previous 34,991
2.54%
Holding current value
$2.01 Million
Previous $1.67 Billion
36.86%
% of portfolio
0.3%
Previous 0.21%
Shares
10 transactions
Others Institutions Holding HALO
# of Institutions
595Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$988 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$719 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$339 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$218 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$206 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.81B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...